Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) versus I-Mab (NASDAQ:NBP) Head-To-Head Review

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) and I-Mab (NASDAQ:NBP – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Lakefront Biotherapeutics American Depositary Shares and I-Mab, as provided by MarketBeat.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $35.50, suggesting a potential upside of 9.98%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 653.14%. Given I-Mab’s higher probable upside, analysts clearly believe I-Mab is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and I-Mab”s top-line revenue, earnings per share (EPS) and valuation.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than I-Mab. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and I-Mab’s net margins, return on equity and return on assets.

Risk & Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Summary

I-Mab beats Lakefront Biotherapeutics American Depositary Shares on 7 of the 11 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About I-Mab

(Get Free Report)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.